Grifols, S.A. (GRFS)
| Market Cap | 6.38B |
| Revenue (ttm) | 7.32B |
| Net Income (ttm) | 65.91M |
| Shares Out | 835.38M |
| EPS (ttm) | 0.10 |
| PE Ratio | 77.00 |
| Forward PE | 14.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 830,003 |
| Open | 7.62 |
| Previous Close | 7.70 |
| Day's Range | 7.54 - 7.69 |
| 52-Week Range | 5.30 - 12.15 |
| Beta | 0.67 |
| Analysts | Sell |
| Price Target | 10.50 (+37.53%) |
| Earnings Date | Jul 28, 2022 |
About GRFS
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and... [Read more]
Financial Performance
In 2023, Grifols's revenue was 6.59 billion, an increase of 8.71% compared to the previous year's 6.06 billion. Earnings were 59.32 million, a decrease of -71.52%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for GRFS stock is "Sell." The 12-month stock price forecast is $10.5, which is an increase of 37.53% from the latest price.
News
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Advanced Solid Tumors
GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with CTLA-4 blockade
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Gr...
Grifols swings to profit, says debt reduction on track
Spanish drugmaker Grifols swung to a first-quarter net profit of 21 million euros ($23 million) from a year-ago loss, and said on Tuesday it was on track to meet its 2024 outlook, including cutting de...
Grifols 2023 Annual Report on Form 20-F filed with the SEC
BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, toda...
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
BARCELONA, Spain, April 18, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today officially celeb...
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
Spanish drug maker Grifols , battling a plunge in its share price this year, plans to add independent directors to its audit and compensation committees to improve its governance, its chairman said in...
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake
Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("G...
Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor
Spanish drugmaker Grifols on Thursday issued new details of its 2022 and 2023 accounts, including higher leverage ratios than previously reported based on a different calculation of its core earnings ...
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS
NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS).
Shares in Spanish drugmaker Grifols tumble on Fitch, S&P downgrades
Shares in Grifols fell more than 9% on Thursday after credit rating agencies Fitch and S&P downgraded their ratings for the beleaguered Spanish drugmaker, citing lower than expected free cash flow gen...
Grifols shares drop to 12-year low after new Gotham City Research report
Shares in Spanish drugmaker Grifols fell to a 12-year low on Wednesday, following the publication of a new report by Gotham City Research questioning the financial accounts of the Barcelona-based comp...
Grifols shares drop 15% after new Gotham City Research report
Shares in Spanish drugmaker Grifols fell nearly 15% in early trading on Wednesday following the publication of a new report by Gotham City Research questioning the Barcelona-based company's "transpare...
Grifols says due diligence done, Shanghai RAAS stake sale to go ahead
Grifols' $1.8 billion sale of a 20% stake in Shanghai RAAS will proceed after a due diligence process concluded "satisfactorily", the Spanish drug maker said on Friday.
Grifols CEO Glanzmann to become non-executive chairman in 2025
Spanish drug maker Grifols' top executive Thomas Glanzmann said on Thursday he will become non-executive chairman in 2025 as part of the beleaguered company's management overhaul. Glanzmann, who is cu...
Gotham City issues new report on Grifols, maintains questions over accounting practices
Short-seller fund Gotham City Research on Tuesday issued a second report on Grifols , maintaining some of its questions over the Spanish pharmaceutical company's accounting practices.
Grifols announces positive topline phase 3 fibrinogen clinical trial results
BARCELONA, Spain, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced that Biotest's positi...
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / February 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A....
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF
NEW YORK , Jan. 26, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Grifols, S.A. (NASDAQ...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / January 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ...
Spanish supervisor analysing Grifols' response to Gotham City report
Spanish stock market supervisor said on Tuesday it is analysing the response from drugmaker Grifols to the allegations in a report from short-seller Gotham City which questioned its financial accounts...
Grifols to respond "very, very soon", before deadline, to supervisor request - board member
Grifols will send "very, very soon" its responses to a query made by Spain's CNMV stock market supervisor, in advance of reaching a ten-day deadline that expires next week, Grifols' board member Tomas...